ロード中...
Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors
Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failu...
保存先:
| 出版年: | Mol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6210052/ https://ncbi.nlm.nih.gov/pubmed/30133130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12375 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|